Acadian Asset Management
ACHL

Acadian Asset Management’s Achilles Therapeutics ACHL Stock Holding History

Acadian Asset Management’s Portfolio ACHL Stock Details ACHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-191,829
Closed -$218K – 1855
2024
Q4 		$218K Sell
191,829
-58,996
-24% -$60.8K ﹤0.01% 1247
2024
Q3 		$255K Hold
250,825
– – ﹤0.01% 1281
2024
Q2 		$203K Sell
250,825
-30,104
-11% -$26.5K ﹤0.01% 1423
2024
Q1 		$350K Buy
+280,929
New +$303K ﹤0.01% 1085
2022
Q4 		– Sell
-1,268
Closed -$2K – 1944
2022
Q3 		$2K Buy
+1,268
New +$3.59K ﹤0.01% 1650

Other funds holding ACHL

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
BAM
Brave Asset Management Summit, New Jersey $467M AUM 33.05% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Acadian Asset Management's ACHL Position: Q1 2025 in Review

Acadian Asset Management sold out of Achilles Therapeutics (ACHL) in Q1 2025, closing a stake of 191,829 shares — an estimated $218K sold.

Acadian Asset Management first reported a position in ACHL in Q3 2022 and held it in 5 quarters. The position peaked at $350K in Q1 2024. 6 funds tracked by Wall St. Rank hold ACHL as of Q1 2025.

  • Acadian Asset Management reported no remaining Achilles Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Acadian Asset Management sold 191,829 Achilles Therapeutics shares in Q1 2025, an estimated $218K.
  • Acadian Asset Management first reported a position in Achilles Therapeutics in Q3 2022 and held it in 5 quarters.
  • Acadian Asset Management's Achilles Therapeutics position peaked at $350K in Q1 2024.
  • 6 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q1 2025.

Based on Acadian Asset Management's 13F filing for Q1 2025, filed 21 May 2025.